Overview
Insulin glargine is a long-acting insulin and antidiabetic medication used for Blood Sugar management when prescribed. Common brand names may include Lantus, Basaglar, Toujeo, and Semglee. Insulin glargine is not the same as rapid-acting insulin and should not be used as sliding scale insulin unless the provider order specifically identifies the insulin type and instructions.
For home health nurses, Insulin Glargine indication and home health teaching often focuses on Blood Sugar management, insulin safety, hypoglycemia awareness, injection safety, medication compliance, storage reminders, Blood Sugar reporting, sick-day/provider instruction reminders, and when to notify PCP or call 911. This post also includes short EMR indication options for Insulin Glargine to help nurses choose brief, diagnosis-specific wording for medication indication fields.
Common indications may include Blood Sugar management in patients with type 1 diabetes mellitus or type 2 diabetes mellitus when ordered. FDA labeling for Lantus identifies insulin glargine as a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Lantus labeling also notes it is not recommended for treating diabetic ketoacidosis. MedlinePlus describes insulin glargine as a long-acting synthetic version of human insulin and lists use in type 1 diabetes and type 2 diabetes.
Insulin glargine may help manage Blood Sugar as ordered, but it does not cure diabetes. Patient-specific dosing, timing, route, storage, administration, and Blood Sugar reporting instructions must always follow provider order, medication profile, pharmacy label, plan of care, and agency policy.
Medication Quick Information
| Item | Information |
|---|---|
| Generic name | Insulin glargine |
| Common brand name(s) | Lantus, Basaglar, Toujeo, Semglee |
| Drug classification | Long-acting insulin / antidiabetic medication |
| Common home health teaching focus | Blood Sugar management, insulin safety, hypoglycemia awareness, injection safety, medication compliance, storage reminders, Blood Sugar reporting, sick-day/provider instruction reminders, and when to notify PCP or call 911 |
Common Indications for Insulin Glargine
Common indications may include:
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Blood Sugar management
- Long-acting insulin therapy
- Basal insulin therapy
- Diabetes medication management
- Hyperglycemia management as part of provider-ordered diabetes plan
Insulin glargine is a long-acting insulin. It should not be confused with rapid-acting insulin, short-acting insulin, premixed insulin, or sliding scale insulin. DailyMed labeling warns that accidental mix-ups between insulin products can occur and instructs patients to check insulin labels before injection.
Drug classification is not the same as patient-specific indication. For example, insulin glargine may be classified as long-acting insulin, but the patient-specific indication may be type 1 diabetes, type 2 diabetes, Blood Sugar management, basal insulin therapy, or another provider-ordered diabetes-related reason.
Short EMR Indication Options
Verify patient-specific reason before use. The examples below are possible short indication options. Select only the indication that matches the patient’s diagnosis, provider order, medication profile, discharge instructions, pharmacy label, or clarified PCP/provider instruction.
| Patient diagnosis / reason | Short EMR indication option |
|---|---|
| Type 1 diabetes mellitus | Type 1 diabetes management |
| Type 2 diabetes mellitus | Type 2 diabetes management |
| Diabetes mellitus | Diabetes / Blood Sugar control |
| Hyperglycemia | Hyperglycemia management |
| Long-acting insulin therapy | Long-acting insulin therapy |
| Basal insulin therapy | Basal insulin therapy |
| Diabetes medication support | Diabetes medication management |
| Blood Sugar management plan | Blood Sugar management |
Home Health Teaching Focus
For home health nursing, Insulin Glargine teaching often focuses on medication compliance, Blood Sugar monitoring if ordered, hypoglycemia awareness, injection safety, insulin product verification, storage reminders, sharps disposal, sick-day/provider instruction reminders, and when to notify PCP or call 911.
Patients may need reinforcement if they have a new insulin order, recent Hospital stay, abnormal Blood Sugar readings, hypoglycemia episodes, hyperglycemia episodes, poor intake, vomiting, diarrhea, infection, vision limitations, hand dexterity problems, cognitive concerns, medication confusion, unsafe injection technique, PCG involvement, or difficulty following the diabetes care plan.
Patient Teaching Points for Insulin Glargine
Basic teaching may include:
- Use Insulin Glargine exactly as ordered by PCP/provider.
- Do not stop, skip, hold, take extra, or change insulin unless instructed by PCP/provider.
- Check Blood Sugar only as ordered or instructed.
- Verify insulin name and label before use to avoid mix-ups with other insulin types.
- Report repeated high or low Blood Sugar readings as instructed.
- Report shakiness, sweating, confusion, dizziness, weakness, poor intake, vomiting, diarrhea, infection symptoms, or symptoms that worsen.
- Follow provider instructions for sick days, poor intake, procedures, or Hospital visits.
- Keep updated medication list and insulin information available for PCP, pharmacy, home health agency, and Hospital visits.
- Ask PCP or pharmacist if confused about insulin name, storage, injection instructions, or Blood Sugar reporting.
Possible Side Effects or Concerns to Report
Possible side effects or concerns may include:
- low Blood Sugar symptoms
- shakiness
- sweating
- dizziness
- weakness
- confusion
- headache
- hunger
- fast heartbeat
- sleepiness or trouble waking
- high Blood Sugar readings
- injection site redness, swelling, itching, or irritation
- skin changes at injection areas
- weight changes or swelling concerns
- allergic reaction symptoms
- low potassium concern if instructed by provider
DailyMed labeling for Lantus includes warnings and precautions related to hypoglycemia, medication errors from insulin product mix-ups, severe hypersensitivity reactions, hypokalemia, and fluid retention/heart failure when used with certain medications such as thiazolidinediones. MedlinePlus notes insulin glargine can cause changes in Blood Sugar and that patients should know symptoms of low and high Blood Sugar and what to do if they have these symptoms.
When to Notify PCP
Call PCP or follow agency/provider instructions if patient has:
- repeated low Blood Sugar readings
- repeated high Blood Sugar readings
- shakiness, sweating, dizziness, confusion, weakness, or other low Blood Sugar symptoms
- Blood Sugar readings outside provider-ordered reporting parameters
- poor intake, vomiting, diarrhea, fever, infection, or dehydration concerns
- insulin product confusion or possible insulin error
- injection site redness, swelling, drainage, or worsening irritation
- difficulty using insulin pen, syringe, needle, or supplies safely
- medication confusion
- refill or supply problems
- symptoms that continue or worsen
When to Call 911
Call 911 or get emergency help right away for:
- severe low Blood Sugar symptoms not improving with ordered treatment plan
- unresponsiveness
- seizure
- severe confusion or sudden mental status change
- inability to safely swallow or respond
- severe weakness with trouble responding
- severe trouble breathing
- chest pain or chest pressure
- severe allergic reaction symptoms
- severe swelling of face, lips, tongue, or throat
- symptoms that feel severe or life-threatening
Important Use Note
This post is for education and home health teaching support only. It does not provide dosing advice, sliding scale instructions, independent insulin adjustment instructions, or patient-specific medication profile fields.
Always verify patient-specific Insulin Glargine use, indication, dosing, timing, administration instructions, storage instructions, Blood Sugar monitoring, and reporting parameters with provider order, medication profile, discharge instructions, pharmacy label, plan of care, agency policy, and clinical judgment. Drug classification is not the same as patient-specific indication.
Insulin glargine is long-acting insulin. Do not confuse it with rapid-acting insulin, short-acting insulin, premixed insulin, or sliding scale insulin.
Public Premium Teaser
Need copy-friendly Insulin Glargine teaching and documentation support for home health notes?
The Premium Library section includes a home health teaching script, detailed patient/PCG teaching points, SN charting phrases, patient/PCG response phrases, ongoing skilled need wording, weak vs stronger documentation examples, and a quick charting template for Insulin Glargine teaching.
Restricted Premium Library Section
Suggested restriction note:
Premium teaching and documentation support below is available for Premium Library and Agency Inservice Library members.
Premium Library Teaching and Documentation Support
Sources Used for Medication Information
- DailyMed / FDA prescribing label for Lantus/insulin glargine, including listed indication to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus, and limitation that it is not recommended for diabetic ketoacidosis.
- DailyMed / FDA labeling warning that insulin product mix-ups may occur and patients should check insulin labels before injection.
- MedlinePlus medication information for insulin glargine, including long-acting insulin description and use in type 1 and type 2 diabetes.
- Patient-specific use should always be verified with provider order, medication profile, discharge instructions, pharmacy label, agency policy, and clinical judgment.
Leave a Reply